Sobetirome

• CAT Number: I002623
• CAS Number: 211110-63-3
• Molecular Formula: C20H24O4
• Molecular Weight: 328.41
• Purity: ≥95%
• Synonyms: GC-1; GC1; GC 1; QRX-431; QRX 431; QRX431; Sobetirome; 2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
• Target: Thyroid Hormone Receptor
• Solubility: in DMSO > 10 mM
• Storage: Store at -20°C
• IUPAC Name: 2-[4-[(4-hydroxy-3-propan-2-ylphenyl)methyl]-3,5-dimethylphenoxy]acetic acid
• InChI: InChI=1S/C20H24O4/c1-12(2)17-9-15(5-6-19(17)21)10-18-13(3)7-16(8-14(18)4)24-11-20(22)23/h5-9,12,21H,10-11H2,1-4H3,(H,22,23)
• InChIKey: QNAZTOHXCZPOSA-UHFFFAOYSA-N
• SMILES: CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCC(=O)O

Sobetirome(CAT: I002623) is a potent and selective thyroid hormone receptor (TR) β-agonist, designed to mimic the metabolic effects of thyroid hormones without affecting the heart or bone. By selectively activating TRβ, Sobetirome promotes lipid metabolism and cholesterol clearance, making it a promising compound for research into metabolic diseases such as hypercholesterolemia, non-alcoholic fatty liver disease (NAFLD), and obesity. Its high selectivity for TRβ over TRα minimizes off-target effects, offering a safer profile for potential therapeutic applications. Sobetirome is a valuable tool in studying thyroid hormone signaling pathways and developing targeted treatments for metabolic disorders.